Display options
Cite
Olivan M, Garcia M, Suárez L, et al. Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246202.
Olivan, M., Garcia, M., Suárez, L., Guiu, M., Gros, L., Méndez, O., Rigau, M., Reventós, J., Segura, M. F., de Torres, I., Planas, J., de la Cruz, X., Gomis, R. R., Morote, J., Rodríguez-Barrueco, R., & Santamaria, A. (2021). Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers, 13(24), . https://doi.org/10.3390/cancers13246202
Olivan, Mireia, et al. "Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246202
Olivan M, Garcia M, Suárez L, Guiu M, Gros L, Méndez O, Rigau M, Reventós J, Segura MF, de Torres I, Planas J, de la Cruz X, Gomis RR, Morote J, Rodríguez-Barrueco R, Santamaria A. Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers (Basel). 2021 Dec 09;13(24). doi: 10.3390/cancers13246202. PMID: 34944822.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 09;13(24). doi: 10.3390/cancers13246202.

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.

Cancers

Mireia Olivan, Marta Garcia, Leticia Suárez, Marc Guiu, Laura Gros, Olga Méndez, Marina Rigau, Jaume Reventós, Miguel F Segura, Inés de Torres, Jacques Planas, Xavier de la Cruz, Roger R Gomis, Juan Morote, Ruth Rodríguez-Barrueco, Anna Santamaria

Affiliations

  1. Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), 08907 L'Hospitalet de Llobregat, Spain.
  2. Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
  3. Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain.
  4. Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain.
  5. Cancer Science Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain.
  6. Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
  7. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
  8. Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, 08017 Barcelona, Spain.
  9. Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
  10. Department of Pathology, University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
  11. Department of Urology, University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
  12. Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
  13. Group of Clinical and Translational Bioinformatics, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

PMID: 34944822 DOI: 10.3390/cancers13246202

Abstract

About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the

Keywords: bone metastasis; miRNA-135b; miRNAs; prostate cancer

References

  1. Mol Cell. 2018 Jan 4;69(1):87-99.e7 - PubMed
  2. Methods Mol Biol. 2021;2294:253-267 - PubMed
  3. Clin Exp Metastasis. 2014 Mar;31(3):269-83 - PubMed
  4. Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):808-819 - PubMed
  5. Clin Exp Metastasis. 2003;20(4):327-34 - PubMed
  6. Biomed J. 2020 Apr;43(2):163-173 - PubMed
  7. Mol Ther Nucleic Acids. 2019 Jun 7;16:91-104 - PubMed
  8. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1309-1315 - PubMed
  9. Stem Cells. 2009 Aug;27(8):1712-21 - PubMed
  10. Urol Oncol. 2018 Aug;36(8):349-360 - PubMed
  11. Cancers (Basel). 2021 Sep 06;13(17): - PubMed
  12. Mol Oncol. 2015 Aug;9(7):1287-300 - PubMed
  13. J Urol. 2005 Sep;174(3):820-6 - PubMed
  14. Cancers (Basel). 2021 May 29;13(11): - PubMed
  15. Int J Oncol. 2015 Aug;47(2):710-8 - PubMed
  16. Int J Oncol. 2013 Apr;42(4):1473-81 - PubMed
  17. Oncogene. 2012 Nov 22;31(47):4935-45 - PubMed
  18. Clin Chim Acta. 2015 Dec 7;451(Pt B):154-60 - PubMed
  19. Oncol Rep. 2018 Jan;39(1):81-90 - PubMed
  20. Nucleic Acids Res. 2010 Jan;38(Database issue):D480-7 - PubMed
  21. Cancer Res. 2017 Feb 15;77(4):1021-1034 - PubMed
  22. Nucleic Acids Res. 2014 Jan;42(Database issue):D199-205 - PubMed
  23. Prostate Cancer Prostatic Dis. 2012 Dec;15(4):314-9 - PubMed
  24. J Transl Med. 2011 Oct 28;9:185 - PubMed
  25. Int J Urol. 2016 Oct;23(10):825-832 - PubMed
  26. Mol Cancer. 2017 Jul 10;16(1):117 - PubMed
  27. Mol Cell Biochem. 2014 Mar;388(1-2):249-59 - PubMed
  28. Nat Methods. 2015 Aug;12(8):697 - PubMed
  29. Nat Med. 2013 Nov;19(11):1423-37 - PubMed
  30. Bonekey Rep. 2015 May 13;4:688 - PubMed
  31. Oncol Rep. 2017 Feb;37(2):803-812 - PubMed
  32. Curr Pharm Biotechnol. 2011 Nov;12(11):1900-8 - PubMed
  33. IUBMB Life. 2014 Jun;66(6):379-86 - PubMed
  34. J Biol Chem. 2005 Mar 18;280(11):10478-83 - PubMed
  35. Br J Cancer. 2015 Sep 29;113(7):1055-65 - PubMed
  36. Nat Commun. 2013;4:1877 - PubMed
  37. Oncotarget. 2018 Feb 17;9(17):13894-13910 - PubMed
  38. Prostate. 2014 May;74(7):756-67 - PubMed
  39. Oncol Rep. 2016 Dec;36(6):3707-3715 - PubMed
  40. PLoS One. 2016 Jul 22;11(7):e0159601 - PubMed
  41. Oncol Rep. 2017 Sep;38(3):1411-1419 - PubMed
  42. Cancer Metastasis Rev. 2010 Dec;29(4):751-9 - PubMed
  43. Nat Rev Urol. 2010 May;7(5):286-97 - PubMed
  44. J Exp Clin Cancer Res. 2017 Aug 11;36(1):108 - PubMed
  45. FEBS Open Bio. 2020 Apr;10(4):674-688 - PubMed
  46. Cancer Sci. 2016 Jan;107(1):84-94 - PubMed
  47. Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):547-554 - PubMed
  48. Biochim Biophys Acta. 2014 Sep;1843(9):2055-66 - PubMed
  49. Mol Ther Nucleic Acids. 2019 Jun 7;16:229-245 - PubMed
  50. Exp Cell Res. 2008 Jul 1;314(11-12):2199-211 - PubMed
  51. Int J Mol Sci. 2017 Dec 19;18(12): - PubMed
  52. Cancer Cell. 2014 Apr 14;25(4):469-83 - PubMed
  53. Cancer Res. 2011 Mar 1;71(5):1956-67 - PubMed
  54. J Exp Clin Cancer Res. 2019 Jan 21;38(1):26 - PubMed
  55. Int J Oncol. 2007 Apr;30(4):765-74 - PubMed
  56. Clin Pharmacol Ther. 2012 Oct;92(4):414-7 - PubMed
  57. Biomed Pharmacother. 2020 Apr;124:109863 - PubMed
  58. BJU Int. 2014 May;113(5b):E164-77 - PubMed
  59. Cancer Cell. 2016 Dec 12;30(6):836-848 - PubMed
  60. Oncotarget. 2015 Aug 21;6(24):20434-48 - PubMed
  61. Cancer Cell Int. 2020 Apr 25;20:134 - PubMed
  62. Nucleic Acids Res. 2018 Jan 4;46(D1):D380-D386 - PubMed
  63. Int J Biol Sci. 2021 May 10;17(8):1940-1952 - PubMed
  64. J Cell Biochem. 2003 Jun 1;89(3):462-73 - PubMed
  65. Biochem J. 2012 Apr 15;443(2):387-96 - PubMed
  66. J Cell Biochem. 2008 Jan 1;103(1):30-41 - PubMed
  67. Oncogene. 2019 Aug;38(35):6241-6255 - PubMed
  68. J Biosci. 2019 Sep;44(4): - PubMed
  69. Nat Rev Cancer. 2011 Jun;11(6):411-25 - PubMed
  70. Theranostics. 2019 Aug 14;9(21):6063-6079 - PubMed
  71. Sci Signal. 2013 Apr 02;6(269):pl1 - PubMed
  72. Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W451-4 - PubMed
  73. Oncogene. 2016 Mar 3;35(9):1180-92 - PubMed
  74. Cell Death Dis. 2013 Nov 21;4:e928 - PubMed
  75. Clin Transl Oncol. 2019 Feb;21(2):126-144 - PubMed
  76. Oncol Lett. 2016 Jan;11(1):543-550 - PubMed
  77. Cell Death Differ. 2019 May;26(5):843-859 - PubMed
  78. Int J Mol Sci. 2012;13(2):1951-2011 - PubMed
  79. PLoS One. 2014 Jul 15;9(7):e102621 - PubMed
  80. Genome Biol. 2010;11(8):R90 - PubMed
  81. Prostate. 2013 Jul;73(10):1048-56 - PubMed
  82. Int J Mol Med. 2020 Mar;45(3):703-714 - PubMed
  83. Endocr Relat Cancer. 2016 Aug;23(8):609-23 - PubMed
  84. Nat Rev Cancer. 2017 May;17(5):302-317 - PubMed
  85. J Bone Oncol. 2017 Sep 11;9:1-9 - PubMed
  86. J Cell Physiol. 2019 Jul;234(7):10819-10826 - PubMed
  87. J Bone Oncol. 2016 Jul 08;5(3):104-108 - PubMed
  88. Semin Cancer Biol. 2017 Jun;44:170-181 - PubMed
  89. Cancer Lett. 2017 Oct 28;407:9-20 - PubMed
  90. Am J Cancer Res. 2017 Aug 01;7(8):1738-1753 - PubMed
  91. Cancer Res. 2009 Feb 15;69(4):1685-92 - PubMed
  92. Biomed Pharmacother. 2018 Jan;97:120-127 - PubMed
  93. Oncotarget. 2015 Jan 1;6(1):441-57 - PubMed
  94. Oncotarget. 2015 Oct 6;6(30):29161-77 - PubMed
  95. Elife. 2015 Aug 12;4: - PubMed

Publication Types